Personalized Medicine Needs a Statistical Makeover | Diaceutics

Personalized Medicine Needs a Statistical Makeover

September 17th, 2013

Aiden Flynn

Aiden Flynn, Exploristics, highlights how early engagement with statisticians in personalized medicine planning would enable the identification of many more biomarkers with clinical utility and reveal the revenue opportunity for a particular therapy. 

As a statistician, I believe I can add most value to an experiment during the planning phase and before any data are collected by ensuring the design offers the best chance of meeting the study objectives. Therefore, it is frustrating that statisticians are regularly ignored during the planning of a study and only get involved once the data have been collected. At this stage, it is often too late to salvage the experiment and it becomes an exercise in sifting through the detritus looking for remnants of information. Whilst statisticians can make retrospective analysis look like a well-executed, professional undertaking by producing some pretty pictures, this can amount to giving a pig a full makeover.

The concept of proper planning is particularly relevant in personalized medicine research because much of the focus to date has been on sample collection, the generation of huge volumes of biomarker data and the analysis of these data rather than the prospective design of the experiments.  Whilst it is possible to identify some useful biomarkers from a retrospective analysis (e.g., KRAS), there is no doubt that retrospective analysis in poorly-designed experiments suffers from a very low chance of success. At Exploristics, we have shown that it is possible to design exploratory personalized medicine studies to achieve a high probability of success.  We have developed and applied a novel approach, based on computer simulation, to optimize studies designed to meet multiple objectives, such as the investigation of efficacy in the entire study population, as well as in a subgroup. In one application, we estimated the probability of success in identifying a genetically defined subgroup to range from zero, for an entirely retrospective approach, to more than 60 per cent for a more prospective approach. This can be achieved by smarter stratification and allocation of subjects within and between treatment groups and by selecting a more appropriate method for analyzing the data, all without compromising the likelihood of success for the other objectives or adding to the cost of the study.

The early engagement of statisticians and the application of novel study designs will shift the likelihood of success to a level that will enable the identification of many more biomarkers with clinical utility, lead to a fold-change in the return on investment, create an irrefutable momentum that will change the personalized medicine cultural landscape and, consequently, will ensure that personalized medicine really is an integral part of drug development planning process. Personalized medicine would greatly benefit from a statistical makeover, but one with real substance – if it involves a pig, it’s too late.

 

 

Blogs

View all blogs

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications